ALSO READGlenmark Pharma receives USFDA nod for skin lotion Glenmark Pharma releases investigational skin findings Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma Glenmark Pharma gets healthier after entering into agreement Glenmark Pharma gains after USFDA approval for drug
Conducts first-in-human, open-label study for dosing of GBR 1342Glenmark Pharmaceuticals announced that the first patient has been dosed in a Phase 1 trial of GBR 1342 (NCT03309111), an investigational bispecific antibody.
This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached. Additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti-tumor activity.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)